Ivacaftor
- TRADE NAME: Kalydeco (Vertex)
- INDICATIONS: Cystic fibrosis in patients aged 6 years and older who have a G551D mutation in the CFTR gene
- CLASS: CFTR potentiator
- HALF-LIFE: 12 hours
FDA APPROVAL DATE: 01/31/2012
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A inducers or inhibitors, Fluconazole, Grapefruit Juice, Ketoconazole, Rifampin, St John's Wort
PREGNANCY CATEGORY: B
See also separate profiles for lumacaftor/ivacaftor and tezacaftor/ivacaftor.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ivacaftor in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric